Scarica l'app Stockscreener
88.08
5.18%
4.34
Dopo l'orario di chiusura:
88.20
0.12
+0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché NVO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$83.74
Aprire:
$88.39
Volume 24 ore:
15.00M
Relative Volume:
1.84
Capitalizzazione di mercato:
$390.99B
Reddito:
$42.09B
Utile/perdita netta:
$14.65B
Rapporto P/E:
26.83
EPS:
3.2833
Flusso di cassa netto:
$10.11B
1 W Prestazione:
+13.11%
1M Prestazione:
+8.70%
6M Prestazione:
-34.74%
1 anno Prestazione:
-27.16%
Intervallo 1D:
$85.74
$89.23
Intervallo di 1 settimana:
$81.06
$89.23
Portata 52W:
$77.82
$148.15
Novo Nordisk Adr Stock (NVO) Company Profile
Nome
Novo Nordisk Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NVO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-12 | Iniziato | Morgan Stanley | Equal-Weight |
| 2025-01-06 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | Iniziato | Goldman | Buy |
| 2024-04-12 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-23 | Iniziato | Morgan Stanley | Overweight |
| 2024-01-16 | Ripresa | UBS | Neutral |
| 2023-12-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-02 | Iniziato | Argus | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2022-07-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | Downgrade | UBS | Neutral → Sell |
| 2022-06-27 | Aggiornamento | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-05-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-04-25 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2022-04-12 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-01-25 | Downgrade | Liberum | Hold → Sell |
| 2021-12-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-17 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-01-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | Iniziato | Deutsche Bank | Buy |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-07-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-05-11 | Downgrade | UBS | Buy → Neutral |
| 2020-05-04 | Iniziato | Cowen | Market Perform |
| 2020-03-16 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-11-18 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-09-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-08-30 | Downgrade | Jefferies | Hold → Underperform |
| 2019-06-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2019-06-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2019-04-29 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | Iniziato | Exane BNP Paribas | Outperform |
| 2018-12-11 | Ripresa | Jefferies | Hold |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2017-12-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2017-12-06 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
Mostra tutto
Novo Nordisk Adr Borsa (NVO) Ultime notizie
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Are Investors Inclined To Sell Their Novo Nordisk ADR (NYSE: NVO) Holdings? - Stocks Register
The Attractiveness of Investing In Novo Nordisk ADR (NVO) is Growing - Knox Daily
Ero Copper Corp (ERO) gets rating Initiated from Goldman - Knox Daily
Itau Unibanco Holding S.A. ADR (ITUB) Stock Records -5.92% Quarterly Movement - The News Heater
Novo Nordisk ADR (NVO) Shares Decline Despite Market Challenges - The News Heater
A Stock Analysis Of Novo Nordisk ADR’s (NVO) - Stocks Register
Examining Novo Nordisk ADR (NVO) more closely is necessary - US Post News
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up - MSN
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth - Morningstar
Novo Nordisk ADR [NVO] Is Currently -0.04 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Novo Nordisk Stock Rises After Earnings. It Expects Good News From the FDA. - Barron's
Novo Nordisk Shares Surge on Strong Sales of Wegovy, Despite Slight Earnings Miss – market - HPBL
Novo Nordisk Stock Up After Earnings. Weight-Loss Drugmaker Sees Slower Growth. - Barron's
Novo Nordisk ADR earnings beat by $5.46, revenue topped estimates - Investing.com Nigeria
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/SNVO - cnhinews.com
Novo Nordisk ADR (NVO) Stock: A Look at the Analyst Recommendations - The News Heater
Novo Nordisk: Next-Generation GLP-1/Amylin Drug Sees Leading Weight Loss in Small Trial - Morningstar
2 Companies Poised to Capitalize on the Rise of GLP-1 Drugs - Morningstar
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
Novo Nordisk Adr Azioni (NVO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):